In the present study, we report the 52‐week safety and efficacy of tofogliflozin when administered to patients with type 2 diabetes mellitus who were treated with GLP‐1 receptor agonist monotherapy, but were controlled inadequately. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.